Target intelligence / Profile preview

Gut microbial community composition (GM)

Target
GM
Molecular classification
Other
01

Overview

The gut microbial community composition, commonly known as the gut microbiota, refers to the vast and diverse population of microorganisms, including bacteria, archaea, fungi, and viruses, that reside in the human digestive tract. This complex ecosystem functions as a metabolic organ, contributing to the breakdown of dietary fibers into short-chain fatty acids, the synthesis of vitamins K and B12, and the maintenance of the intestinal mucosal barrier (NIH, 2023). Beyond local digestion, the gut microbiota plays a pivotal role in systemic health by modulating the host's immune system and communicating with the central nervous system via the gut-brain axis (Nature Reviews Microbiology, 2022). Dysbiosis, or the pathological alteration of this community's composition, is a hallmark of several diseases, most notably recurrent Clostridioides difficile infection and inflammatory bowel disease (PubMed, 2021). Therapeutic interventions, such as fecal microbiota transplantation and defined microbial consortia like SER-109, target this community to restore ecological balance and suppress pathogen overgrowth (FDA, 2023). As research progresses, the gut microbiota is increasingly recognized as a modifiable target for treating metabolic, autoimmune, and even neuropsychiatric conditions.

Other names
Gut microbiotaGut microbiomeIntestinal floraGastrointestinal microbiotaIntestinal microbiota
02

Mechanism of action

Restoration of microbial diversity and ecological balance to suppress pathogen overgrowth, competitive exclusion, and modulation of host inflammatory and metabolic pathways.

03

Biological functions

Metabolic homeostasisImmune system maturationPathogen colonization resistanceVitamin synthesisSignal transductionMaintenance of mucosal barrier integrity
04

Disease associations

Clostridioides difficile infectionInflammatory bowel diseaseObesityIrritable bowel syndromeType 2 diabetesColorectal cancerMetabolic syndrome
05

Safety considerations

Transmission of multi-drug resistant organisms (MDROs)Risk of bacteremia or sepsis in immunocompromised patientsUnintended long-term metabolic or immunological consequencesVariability in donor material composition
06

Interacting drugs

Fecal microbiota spores, live-brpk (SER-109)

6 more in the full profile.

07

Biomarkers

Shannon diversity indexAlpha diversityFirmicutes-to-Bacteroidetes ratioAbundance of Faecalibacterium prausnitziiFecal calprotectinShort-chain fatty acid (SCFA) levels

Beyond the preview

Go deeper on Gut microbial community composition (GM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gut microbial community composition (GM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call